Pelagos Pharmaceuticals, Inc.
Wednesday, June 05, 2024
Company Presentation
![Cardiovascular](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Workforce_MTC.png)
Company Presentation Theater 3
Pelagos is a pre-clinical biotech company developing exercise mimetic drugs for diseases of aging. We have 2 small molecule programs targeting previously undrugged nuclear receptors, ERR and REV-ERB, to regulate cellular energetics, mitochondrial biogenesis, and inflammation and increase muscle function and exercise tolerance. Initial indications are heart failure (HFpEF and HFrEF) and obesity with muscle preservation.
![Pelagos Pharmaceuticals, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1822764-1-JPG.jpg)
Company Website:
http://www.pelagospharma.com
Lead Product in Development:
P109: Rev-Erb Agonist for Heart Failure
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Houston
Company HQ State
Texas
Company HQ Country
United States
CEO/Top Company Official
Dan Watkins
Development Phase of Primary Product
Pre-Clinical
Primary Speaker